70 likes | 222 Views
Statistics about snake bite syndromes and outcomes. CMC Vellore 11.3.13. Data. Data from November 2011 – 2012 Total cases – 48 Clinical syndromes Non venomous – 3 (6%) Venomous Neurotoxic:14 (29%) Heamatotoxic:7 (14%) Combined: 24 (50%). Management strategies.
E N D
Statistics about snake bite syndromes and outcomes CMC Vellore 11.3.13
Data • Data from November 2011 – 2012 • Total cases – 48 • Clinical syndromes • Non venomous – 3 (6%) • Venomous • Neurotoxic:14 (29%) • Heamatotoxic:7 (14%) • Combined: 24 (50%)
Management strategies • Premedication:no adrenaline prior to ASV • Supportive medications: • Neostigmine – 3 (6%) • Antibiotic • Amoxycillin clavulunate • Cellulitis
ASV dosing • Indications • Neurotoxic: progressing neuromuscular paralysis • Heamatotoxic: deranged bleeding parameters and clinical bleeding. • ASV dose • Neurotoxic: 10 vials • Heamatotoxic – 8 – 26 vials
Adverse reactions to ASV • Minor – itching and utricaria • 5 (10.4%) • Major – anaphylaxis • 2 (4.1%)
Outcomes • Mechanical ventilation: 11 (22.9%) • Heamodialysis : 6 (12.5%) • Deaths : 0
Snakes identified • In 3 situations • 6%